141 related articles for article (PubMed ID: 38762454)
1. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of geriatric nutritional risk index in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Eur J Surg Oncol; 2024 Jun; 50(6):108323. PubMed ID: 38603867
[TBL] [Abstract][Full Text] [Related]
4. A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Front Immunol; 2023; 14():1217967. PubMed ID: 37954582
[TBL] [Abstract][Full Text] [Related]
5. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
6. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
[TBL] [Abstract][Full Text] [Related]
7. A CT-based novel model to predict pathological complete response of locally advanced esophageal squamous cell carcinoma to neoadjuvant PD-1 blockade in combination with chemotherapy.
Zhou HY; Guo WW; Ou J; Li R; Gui Y; Li L; Fu MY; Zhang XM; Chen TW
Eur J Radiol; 2023 Oct; 167():111065. PubMed ID: 37651827
[TBL] [Abstract][Full Text] [Related]
8.
Wang S; Di S; Lu J; Xie S; Yu Z; Liang Y; Gong T
Thorac Cancer; 2023 Aug; 14(24):2338-2349. PubMed ID: 37424279
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
[TBL] [Abstract][Full Text] [Related]
10. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.
Yehan Z; Sheng Q; Hong Y; Jiayu L; Jun H; Juan J; Min S; Jiaxin Y; Shangzhi H; Yi W; Qifeng W; Xuefeng L; Wenwu H; Xueyan C; Yang L; Zongyao H
Front Immunol; 2024; 15():1312380. PubMed ID: 38726002
[TBL] [Abstract][Full Text] [Related]
11. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
12. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
Hong ZN; Gao L; Weng K; Huang Z; Han W; Kang M
Front Immunol; 2022; 13():836338. PubMed ID: 35300335
[TBL] [Abstract][Full Text] [Related]
13. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
Gao L; Hong ZN; Wu L; Yang Y; Kang M
Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
[TBL] [Abstract][Full Text] [Related]
14. The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Front Immunol; 2022; 13():1015365. PubMed ID: 36505443
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Ann Surg Oncol; 2024 Jan; 31(1):272-283. PubMed ID: 37838648
[TBL] [Abstract][Full Text] [Related]
16. Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.
Chen P; Wang L; Yang X; Feng J
Biomol Biomed; 2024 Jan; 24(1):159-169. PubMed ID: 37597214
[TBL] [Abstract][Full Text] [Related]
17. A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Yang Y; Yi Y; Wang Z; Li S; Zhang B; Sang Z; Zhang L; Cao Q; Li B
BMC Cancer; 2024 Apr; 24(1):460. PubMed ID: 38609892
[TBL] [Abstract][Full Text] [Related]
18. Association between prognosis and lymph node status using
Ohsawa M; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Hirohata R; Kitasaki N; Okada M
World J Surg; 2024 Mar; 48(3):650-661. PubMed ID: 38686781
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis.
Zhang Y; Li H; Yu B; Sun S; Hu Z; Wu X; Zhang Y; Li B; Zhang Y; Xiang J; Wang J; Yu H
Thorac Cancer; 2024 May; 15(13):1072-1081. PubMed ID: 38532546
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
